M D Groves

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
  2. doi Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa
    Dima Suki
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Neurosurg 108:248-57. 2008
  3. doi Leptomeningeal disease
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, Unit 431, Houston, TX 77030, USA
    Neurosurg Clin N Am 22:67-78, vii. 2011
  4. doi New strategies in the management of leptomeningeal metastases
    Morris D Groves
    UT MD Anderson Cancer Center, Department of Neuro Oncology, 1400 Holcombe Blvd, Unit 431, Houston, TX 77030, USA
    Arch Neurol 67:305-12. 2010
  5. pmc Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
    M D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 101:615-20. 2009
  6. doi Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
    Morris D Groves
    Departments of Neuro Oncology, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:229-34. 2009
  7. doi Low grade astrocytoma presenting with visual loss
    Morris D Groves
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Neurooncol 89:49-50. 2008
  8. pmc A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:208-15. 2008
  9. ncbi Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status
    Morris D Groves
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 80:83-90. 2006
  10. ncbi The pathogenesis of neoplastic meningitis
    Morris D Groves
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030, USA
    Curr Oncol Rep 5:15-23. 2003

Collaborators

Detail Information

Publications32

  1. ncbi A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  2. doi Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa
    Dima Suki
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Neurosurg 108:248-57. 2008
    ..The authors tested the hypothesis that patients with metastatic posterior fossa lesions (MPFLs) treated with resection have a higher risk of leptomeningeal disease (LMD) than those with MPFLs treated with stereotactic radiosurgery (SRS)...
  3. doi Leptomeningeal disease
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, Unit 431, Houston, TX 77030, USA
    Neurosurg Clin N Am 22:67-78, vii. 2011
    ....
  4. doi New strategies in the management of leptomeningeal metastases
    Morris D Groves
    UT MD Anderson Cancer Center, Department of Neuro Oncology, 1400 Holcombe Blvd, Unit 431, Houston, TX 77030, USA
    Arch Neurol 67:305-12. 2010
    ..These advances may lead to better treatments for this disease and, ultimately, its prevention...
  5. pmc Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
    M D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 101:615-20. 2009
    ....
  6. doi Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
    Morris D Groves
    Departments of Neuro Oncology, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:229-34. 2009
    ..We chose to measure these molecules in the cerebrospinal fluid (CSF) of melanoma, breast, and lung cancer patients being evaluated for neoplastic meningitis (NM)...
  7. doi Low grade astrocytoma presenting with visual loss
    Morris D Groves
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Neurooncol 89:49-50. 2008
  8. pmc A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:208-15. 2008
    ..IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered...
  9. ncbi Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status
    Morris D Groves
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 80:83-90. 2006
    ....
  10. ncbi The pathogenesis of neoplastic meningitis
    Morris D Groves
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030, USA
    Curr Oncol Rep 5:15-23. 2003
    ..An understanding of the pathogenesis of NM will allow for its earliest possible diagnosis and ultimately lead to therapies targeted at the underlying molecular causes of this devastating condition...
  11. ncbi Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J F de Groot
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 90:89-97. 2008
    ..Carboplatin plus erlotinib is well tolerated but has modest activity in unselected patients. Future trials should be stratified based on optimal molecular or clinical characteristics...
  12. ncbi Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1383-8. 2002
    ....
  13. ncbi Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme
    V A Levin
    Neuro Oncology Unit 431, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    J Neurooncol 78:85-90. 2006
    ..From this, we concluded that the animal studies generally predicted that the two agents would have only a modest effect alone and no additive effect when given in combination to patients...
  14. pmc 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme
    Siew Ju See
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 6:253-8. 2004
    ..This data supports the use of cRA in such patients, but its further evaluation in larger, prospective, controlled studies with or without other noncytotoxic and cytotoxic agents may be warranted...
  15. doi Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment
    Tobias Walbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Future Oncol 6:287-97. 2010
    ..Nevertheless, we anticipate that future biomarkers will have not only the potential to detect LM, but to predict its progression and response to treatment...
  16. doi Biology and therapy of neoplastic meningitis
    Aaron G Mammoser
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030, USA
    Curr Oncol Rep 12:41-9. 2010
    ..This endeavor is being aided by ongoing research into the underlying biology of the metastatic process...
  17. pmc A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Unit 431, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 12:1167-72. 2010
    ..Multiple cytostatic agents can be safely combined with dose-dense temozolomide. The factorial-based phase II portion of this study is currently ongoing...
  18. pmc Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  19. doi Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis
    Dima Suki
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Neurosurgery 64:664-74; discussion 674-6. 2009
    ....
  20. pmc Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  21. ncbi Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710
    Howard Colman
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:818-24. 2006
    ..The aim of this study was to determine whether recombinant human interferon beta-1a (rhIFN-beta), when given after radiation therapy, improves survival in glioblastoma...
  22. ncbi Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU
    C Gomez-Manzano
    Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Oncol 19:359-65. 2001
    ..These observations suggest that overexpression of genes that positively control cell-cycle progression may be useful for increasing the sensitivity of glioma cells to alkylating agents...
  23. ncbi Response of neoplastic meningitis from solid tumors to oral capecitabine
    Pierre Giglio
    Neuro Oncology Department, University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Neurooncol 65:167-72. 2003
    ..We believe capecitabine warrants further investigation in patients with NM. In some patients, its use may result in clinical and radiographic tumor responses, improved quality of life, and possibly increased survival...
  24. ncbi Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract
    Pierre Giglio
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center Brain Tumor Center, Houston, Texas 77030, USA
    Cancer 103:2355-62. 2005
    ..For this report, the authors characterized the clinical course and attempted to identify prognostic factors in patients with NM due to primary malignancies of the GI tract...
  25. pmc Paraneoplastic chorea: case study with autopsy confirmation
    Ivo W Tremont-Lukats
    Neuro Oncology Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 4:192-5. 2002
    ..The florid presentation and the positive findings contrasted with an unremarkable MRI of the brain. This case illustrates the preeminence of symptoms and signs over negative MRI findings in paraneoplastic encephalitis...
  26. pmc Prognostic factors and outcomes in patients with leptomeningeal melanomatosis
    Laura Harstad
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 10:1010-8. 2008
    ..This retrospective analysis confirmed the dismal prognosis associated with LM. The amount of CNS tumor burden at the time of diagnosis of LM did not inversely correlate with survival outcomes, contrary to our hypothesis...
  27. ncbi Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  28. pmc Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients
    Fatima W Khwaja
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery and Winship Cancer Institute, Emory University School of Medicine, 1365C Clifton Road NE, Atlanta, GA 30322, USA
    J Proteome Res 6:559-70. 2007
    ....
  29. ncbi Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  30. ncbi Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma
    Myung Jin Son
    Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul 135 710, Korea
    Int J Oncol 28:1385-92. 2006
    ..These results suggest that optimal biological dosage and scheduling of PEG-IFN-alpha and paclitaxel combination is a potent strategy for glioblastoma patients as a new synergistic anti-endothelial treatment...
  31. ncbi Combination celecoxib and temozolomide in C6 rat glioma orthotopic model
    Seok Gu Kang
    Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Oncol Rep 15:7-13. 2006
    ..05). Collectively, the data suggest that the combination celecoxib and temozolomide may provide a novel and effective approach to the treatment of glioblastoma...
  32. ncbi CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases
    Morris D Groves
    Neurology 66:1609-10; author reply 1609-10. 2006